TY - JOUR
T1 - A Single Institution Retrospective Study of the Clinical Efficacy of Tiotropium Respimat in Never-Smoking Elderly Asthmatics with Irreversible Airflow Limitation
AU - Hara, Johsuke
AU - Kasahara, Kazuo
AU - Ohkura, Noriyuki
AU - Yamamura, Kenta
AU - Sakai, Tamami
AU - Abo, Miki
AU - Ogawa, Naohiko
AU - Saeki, Keigo
AU - Koba, Hayato
AU - Watanabe, Satoshi
AU - Uchida, Yuka
AU - Tambo, Yuichi
AU - Sone, Takashi
AU - Kimura, Hideharu
N1 - Publisher Copyright:
© Georg Thieme Verlag KG Stuttgart. New York.
PY - 2019
Y1 - 2019
N2 - Objective In Japan, most asthma deaths occur among the elderly. We should improve the control of asthma in elderly patients to reduce the number of deaths due to asthma. This retrospective study aimed to evaluate the efficacy of tiotropium Respimat and (Tio-Res) in symptomatic, never-smoking, elderly asthmatics with irreversible airflow limitation despite the use of high-dose inhaled corticosteroids (ICS) plus long-acting β 2 -adrenoceptor agonists (LABA). Methods The Asthma Control Test™ (ACT), pulmonary function tests, morning and evening peak flow (mPEF, ePEF, respectively, evaluated with an ASSESS ® peak flow meter), and respiratory impedance (assessed with MostGraph ®) were measured before and after a minimum of one year of Tio-Res 5 μg/day administration. Sixteen symptomatic, never-smoking asthmatics, aged 75 or over with irreversible airflow limitation despite the use of high-dose ICS plus LABA, were analyzed. Results All patients were female (mean age, 81.6 years). Tio-Res led to statistically significant improvements in the total ACT score (19.9 to 23.6), FVC and FEV 1 (1.97 to 2.14 L and 1.13 to 1.23 L, respectively), and mPEF and ePEF (229.9 to 253.8 L/min and 259.8 to 277.4 L/min, respectively). Tio-Res also resulted in statistically significant improvements in respiratory resistance at 5 Hz (R5), respiratory resistance at 20 Hz (R20), R5-R20, low-frequency reactant indices at 5 Hz (X5), resonant frequency (Fres) and low-frequency reactance area (ALX). Conclusions Our retrospective study suggests that Tio-Res improves symptoms, pulmonary function, and respiratory impedance in symptomatic asthmatics aged 75 or over with irreversible airflow limitation despite the use of high-dose ICS plus LABA.
AB - Objective In Japan, most asthma deaths occur among the elderly. We should improve the control of asthma in elderly patients to reduce the number of deaths due to asthma. This retrospective study aimed to evaluate the efficacy of tiotropium Respimat and (Tio-Res) in symptomatic, never-smoking, elderly asthmatics with irreversible airflow limitation despite the use of high-dose inhaled corticosteroids (ICS) plus long-acting β 2 -adrenoceptor agonists (LABA). Methods The Asthma Control Test™ (ACT), pulmonary function tests, morning and evening peak flow (mPEF, ePEF, respectively, evaluated with an ASSESS ® peak flow meter), and respiratory impedance (assessed with MostGraph ®) were measured before and after a minimum of one year of Tio-Res 5 μg/day administration. Sixteen symptomatic, never-smoking asthmatics, aged 75 or over with irreversible airflow limitation despite the use of high-dose ICS plus LABA, were analyzed. Results All patients were female (mean age, 81.6 years). Tio-Res led to statistically significant improvements in the total ACT score (19.9 to 23.6), FVC and FEV 1 (1.97 to 2.14 L and 1.13 to 1.23 L, respectively), and mPEF and ePEF (229.9 to 253.8 L/min and 259.8 to 277.4 L/min, respectively). Tio-Res also resulted in statistically significant improvements in respiratory resistance at 5 Hz (R5), respiratory resistance at 20 Hz (R20), R5-R20, low-frequency reactant indices at 5 Hz (X5), resonant frequency (Fres) and low-frequency reactance area (ALX). Conclusions Our retrospective study suggests that Tio-Res improves symptoms, pulmonary function, and respiratory impedance in symptomatic asthmatics aged 75 or over with irreversible airflow limitation despite the use of high-dose ICS plus LABA.
KW - Bronchial asthma
KW - Irreversible airflow limitation
KW - Multi-frequency oscillation technique
KW - Never smoking
KW - Tiotropium Respimat
UR - http://www.scopus.com/inward/record.url?scp=85063531042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063531042&partnerID=8YFLogxK
U2 - 10.1055/a-0665-4379
DO - 10.1055/a-0665-4379
M3 - Article
C2 - 30193393
AN - SCOPUS:85063531042
SN - 2194-9379
VL - 69
SP - 211
EP - 217
JO - Drug Research
JF - Drug Research
IS - 4
ER -